This tag is associated with 1 post

Opdivo® (nivolumab): Bristol-Myers Squibb’s Immunotherapy for Melanoma and Lung Cancer

In my inaugural blog post, I mentioned that I was going to break down each of the top 11 blockbuster drugs of 2015 as predicted by Thomson Reuters. As promised, I will start with number one on the list – Opdivo® (nivolumab), which was first approved as second line treatment of melanoma in December of 2014. Background … Continue reading